Takeaway
Guillain-Barré syndrome (GBS) is extremely infrequent among recipients of all vaccines against severe acute respiratory coronavirus 2 (SARS-CoV-2), the risk is outweighed by the protection provided by these vaccines.
Why this matters
The epidemiology of adverse events following immunization against SARS-CoV-2, including GBS, remains incompletely understood, particularly in underdeveloped countries and underserved regions.
Clinicians are now equipped with more in-depth knowledge of the benefit-risk ratio of SARS-CoV-2 immunization, with regards to GBS as a potential adverse event.